Abstract
Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.
Keywords: Therapeutic antibodies, hybridoma, fusion partner, B cells, EBV transformation, miR transformation.
Current Pharmaceutical Design
Title:Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Volume: 22 Issue: 7
Author(s): Xenia A. Glukhova, Olga V. Prusakova, Julia A. Trizna, Michael M. Zaripov, Gaida V. Afanas’eva, Anatoly S. Glukhov, Rimma A. Poltavtseva, Alexei A. Ivanov, Marco Avila-Rodriguez, George E. Barreto, Gjumrakch Aliev and Igor P. Beletsky
Affiliation:
Keywords: Therapeutic antibodies, hybridoma, fusion partner, B cells, EBV transformation, miR transformation.
Abstract: Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.
Export Options
About this article
Cite this article as:
Glukhova A. Xenia, Prusakova V. Olga, Trizna A. Julia, Zaripov M. Michael, Afanas’eva V. Gaida, Glukhov S. Anatoly, Poltavtseva A. Rimma, Ivanov A. Alexei, Avila-Rodriguez Marco, Barreto E. George, Aliev Gjumrakch and Beletsky P. Igor, Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique, Current Pharmaceutical Design 2016; 22 (7) . https://dx.doi.org/10.2174/1381612822666151223102845
DOI https://dx.doi.org/10.2174/1381612822666151223102845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus
Current Medicinal Chemistry The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Editorial
International Journal of Sensors, Wireless Communications and Control Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer
Current Drug Therapy Clinical and Imaging Features of Tumors in the Scapula
Current Medical Imaging Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives
Current Topics in Medicinal Chemistry Impact of Quaternary Structure Dynamics on Allosteric Drug Discovery
Current Topics in Medicinal Chemistry New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets Gender Disparity in Pediatric Diseases
Current Molecular Medicine Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Liposome Technology for Drug Delivery Against Mycobacterial Infections
Current Pharmaceutical Design The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review
Current Medicinal Chemistry Unified Multi-target Approach for the Rational in silico Design of Anti-bladder Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry FDG-PET/CT Radiomics Models for The Early Prediction of Locoregional Recurrence in Head and Neck Cancer
Current Medical Imaging Is There a Role for Antioxidants in the Prevention of Infection-Associated Carcinogenesis and in the Treatment of Infection-Driven Tumors?
Current Topics in Medicinal Chemistry Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry